Aspen Aerogels, Inc. (ASPN)

From the record

Aspen Aerogels, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Aspen Aerogels, Inc.'s 10 filed years say what it did: revenue went from $118 million in fiscal 2016 to $271 million in fiscal 2025, up 9.7% a year; it rose in 5 of 9 years; the deepest fall was 40% from fiscal 2024 to fiscal 2025; net income was positive in 1 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Aspen Aerogels, Inc.'s diluted share count grew about 27.9% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 1 sale (1 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-06 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Aspen Aerogels, Inc. lost about 165 cents for every dollar of shareholders' money, and gross profitability: its products earned about 11 cents per dollar of everything the company owns. Leverage: it owed about 42 cents per dollar of assets, and net share issuance: its share count grew 2.5% over the year (the filed statements).

From the record

Aspen Aerogels, Inc.'s standing among 51 graded names in its industry family: revenue of $271 million in fiscal 2025 ranks in the bottom 32% by size; a net margin of -143.7% ranks in the bottom 9%; revenue growth of 14.5% a year over the last 3 filed years ranks in the top 9% (its annual reports).

From the record

Aspen Aerogels, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Young, Donald R (President and CEO, as filed), filing under that title since 2014-06-12, 12.4 years (top 22% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 4 years (bottom 16%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 20%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Aspen Aerogels, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $157 million against debt of $65 million leaves 22.5% of its assets as net cash, top 7% of its family; cash from operations less capital spending is -1.7% of revenue (bottom 28%); a gross margin of 17% (bottom 26%); research spending of 4.9% of revenue (top 25%) (its annual report).

From the record

Aspen Aerogels, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 14.5% a year over the last three filed years against 9.7% over all 10, speeding up (top 5% of its family); the newest year grew -40.1% (bottom 9%); research spending grew -7.5% a year (bottom 21%); capital spending grew -40.5% a year (bottom 14%) (its annual reports). Aspen Aerogels, Inc. reported 2 product lines in fiscal 2025: Thermal Barrier at $169 million (62%), Energy Industrial at $102 million (38%); 0 of 2 grew against the year before (its annual report).

From the record

Aspen Aerogels, Inc.'s newest year against its own record: revenue of $271 million in fiscal 2025 came in 62.2% below the $717 million its prior three years' pace pointed to (bottom 6% of its family); net income of $390 million against a prior three-year average of $38 million (bottom 3%); a net margin of a loss larger than its revenue against -20.7% before (bottom 8%) (its annual reports).